SKYE Profile
Skye Bioscience, Inc., a biopharmaceutical firm, specializes in the discovery, development, and commercialization of cannabinoid-based therapies aimed at addressing a range of infectious diseases and other health conditions. The company's innovative approach harnesses the therapeutic potential of cannabinoids to create targeted treatments with a focus on advancing patient care and outcomes.
Skye Bioscience's lead product candidate, SBI-100, is currently undergoing Phase I clinical trials for the treatment of glaucoma and ocular hypertension. This compound represents a significant advancement in the field of ocular therapeutics, leveraging cannabinoid-based mechanisms to potentially improve intraocular pressure regulation and vision preservation. In addition to SBI-100, the company is developing SBI-200, which is in preclinical stages. SBI-200 is being investigated for its potential to manage and treat a variety of eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy.
Formerly known as Emerald Bioscience, Inc., Skye Bioscience rebranded in January 2021 to better reflect its strategic focus on cannabinoid research and development. Founded in 2012 and based in San Diego, California, the company has positioned itself at the forefront of cannabinoid-based therapeutic development, with a robust pipeline aimed at leveraging the unique properties of cannabinoids to address unmet medical needs.
Skye Bioscience continues to drive innovation in the biopharmaceutical industry by advancing its cannabinoid-based molecules through rigorous clinical and preclinical evaluations. The company's commitment to research and development in the cannabinoid space aims to provide new therapeutic options and improve the management of chronic and complex eye conditions, contributing to the broader field of medical advancements in ocular health.
|
